Fennec PharmaceuticalsFENC +4.45%54 PS Ratio is 6.63 as of Jun. 27, 2026, which is 77% below its 10-year median of 28.97. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $10.22 (Fairly Valued). The stock has 2 warning signs investors should review. Among 936 Biotechnology companies, Fennec Pharmaceuticals ranks better than 58.55% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Fennec Pharmaceuticals's share price is $11.02.
Fennec Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.66. Hence, Fennec Pharmaceuticals's PS Ratio for today is 6.63.
The historical rank and industry rank for Fennec Pharmaceuticals's PS Ratio or its related term are showing as below:
FENC'
s PS Ratio Range Over the Past 10 Years
Min: 2.45 Med: 28.97 Max: 1692.5
Current: 6.66
During the past 13 years, Fennec Pharmaceuticals's highest PS Ratio was 1692.50. The lowest was 2.45. And the median was 28.97.
FENC's PS Ratio is ranked better than 58.55% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs FENC: 6.66
During the past 13 years, Fennec Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 392.20% per year. The lowest was 201.00% per year. And the median was 296.60% per year.
Back to Basics: PS Ratio
Fennec Pharmaceuticals (NAS:FENC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fennec Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fennec Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Fennec Pharmaceuticals's Share Price of today is $11.02. Fennec Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.66.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Fennec Pharmaceuticals (FENC) has a PS Ratio of 6.63 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fennec Pharmaceuticals and its competitors. This is 77% below median its historical median of 28.97. Over the past decade, Fennec Pharmaceuticals' PS Ratio has ranged from 2.45 to 1,692.50. According to the industry distribution chart, Fennec Pharmaceuticals ranks #388 out of 936 companies in the Biotechnology industry, placing it in the top 41.5%.
Is Fennec Pharmaceuticals' PS Ratio too high?
Fennec Pharmaceuticals' current PS Ratio of 6.63 is 77% below median its 10-year median of 28.97. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 1,692.50. The Biotechnology industry median PS Ratio is 9.17. Fennec Pharmaceuticals' value of 6.63 is 27.7% below this industry median. Based on the distribution chart, Fennec Pharmaceuticals ranks #388 out of 936 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fennec Pharmaceuticals ranks #388 out of 936 companies for PS Ratio. This puts Fennec Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.17. Fennec Pharmaceuticals' value of 6.63 is 27.7% below this benchmark. Historically, Fennec Pharmaceuticals' own PS Ratio has ranged from 2.45 to 1,692.50 over the past decade. While the company's 10-year median is 28.97 vs. the industry median of 9.17, Fennec Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fennec Pharmaceuticals's current PS Ratio of 6.63 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fennec Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fennec Pharmaceuticals's current PS Ratio is 6.63, which is 77% below median its own 10-year median of 28.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Fairly Valued. The stock's GF Value™ is $10.22, compared to a current price of $11.02 — trading 7.8% above its estimated fair value. The current PS Ratio is 6.63, which is 77% below median its 10-year median of 28.97 and 27.7% below the Biotechnology industry median of 9.17. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current PS Ratio is 6.63 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?
Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued.
The current stock price of $11.02 is trading 7.8% above its estimated GF Value™ of $10.22.
GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.
Key valuation signals for FENC:
PS Ratio: 6.63 (77% below median its 10-year median of 28.97)
GF Value™: $10.22 vs. price of $11.02 (7.8% above fair value)
Industry Position: 27.7% below the Biotechnology median (#388 of 936)
No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score
Get the complete analysis for FENC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FENC has been successfully added to your 
